These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24173652)

  • 1. Histological assessment of therapeutic response in breast cancer.
    Horii R; Akiyama F
    Breast Cancer; 2016 Jul; 23(4):540-5. PubMed ID: 24173652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements.
    Nagashima T; Sakakibara M; Kadowaki M; Suzuki TH; Yokomizo J; Ohki Y; Miyoshi T; Kazama T; Nakatani Y; Miyazaki M
    Acta Radiol; 2011 Apr; 52(3):241-6. PubMed ID: 21498357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Herrada J; Iyer RB; Atkinson EN; Sneige N; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 1997 Sep; 3(9):1565-9. PubMed ID: 9815844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thin-section CT evaluation and pathologic correlation of therapeutic effect of neoadjuvant chemotherapy for axillary lymph nodes of clinically node-positive breast cancer patients.
    Ogawa Y; Nishioka A; Nishigawa T; Kubota K; Kariya S; Yoshida S; Tanaka Y; Moriki T; Tochika N
    Oncol Rep; 2003; 10(4):985-9. PubMed ID: 12792757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant treatment of breast cancer: implications for the pathologist].
    Le Guellec S; Perallon R; Alunni JP; Charitansky H; Leaha C; Gonzalez AM; Chateau MC; Simony-Lafontaine J; Jacot W; Gutowski M; Penault-Llorca F; Dalenc F; Lacroix-Triki M
    Ann Pathol; 2011 Dec; 31(6):442-54. PubMed ID: 22172117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy.
    Morohashi S; Yoshizawa T; Seino H; Hirai H; Haga T; Ota R; Wu Y; Yoshida E; Hakamada K; Kijima H
    Oncol Rep; 2016 May; 35(5):2592-8. PubMed ID: 26935647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
    Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
    Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
    Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
    Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
    Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
    Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
    Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
    Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
    Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
    Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of response evaluation methods of neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Wu SK; Jiang ZF; Wang T; Zhang SH; Zhao YB; Yu CZ; Li XB; Yang T; Li GJ
    Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):783-5. PubMed ID: 20021835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the effects of neoadjuvant chemotherapy on lymphatic pathways to sentinel lymph nodes in cases of breast cancer: Usefulness of the indocyanine green-fluorescence method.
    Tsuyuki S; Yamaguchi A; Kawata Y; Kawaguchi K
    Breast; 2015 Jun; 24(3):298-301. PubMed ID: 25802085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.